These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 15530169)

  • 21. Determinants of immunological and virological responses to antiretroviral therapy amongst HIV-infected adults in central Argentina: negative influence of hepatitis C infection.
    Farías AA; Kremer LE; Allende L; Díaz Mdel P; Pisano MB; Contigiani MS; Ré VE
    Trans R Soc Trop Med Hyg; 2013 Jul; 107(7):432-7. PubMed ID: 23761392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience.
    Erhabor O; Ejele OA; Nwauche CA
    Niger J Clin Pract; 2006 Dec; 9(2):128-33. PubMed ID: 17319344
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia.
    Taye S; Lakew M
    BMC Immunol; 2013 May; 14():23. PubMed ID: 23679118
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy.
    Kaufmann GR; Bloch M; Zaunders JJ; Smith D; Cooper DA
    AIDS; 2000 May; 14(8):959-69. PubMed ID: 10853977
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunological rebound after initiation of highly active antiretroviral therapy in treatment-naive patients.
    Blackard JT; Welles SL; Ackerman A; Kalia N; Cohen DE; Mayer KH
    AIDS Res Hum Retroviruses; 2008 Mar; 24(3):499-504. PubMed ID: 18373435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR; Perrin L; Pantaleo G; Opravil M; Furrer H; Telenti A; Hirschel B; Ledergerber B; Vernazza P; Bernasconi E; Rickenbach M; Egger M; Battegay M;
    Arch Intern Med; 2003 Oct; 163(18):2187-95. PubMed ID: 14557216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The predictive role of CD4
    Li CX; Li YY; He LP; Kou J; Bai JS; Liu J; Tian B; Cao LJ; Wang KH; Kuang YQ
    BMC Immunol; 2019 Aug; 20(1):31. PubMed ID: 31455209
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART).
    Torti C; Cologni G; Uccelli MC; Quiros-Roldan E; Imberti L; Airó P; Pirovano S; Patroni A; Tirelli V; Carosi G
    Viral Immunol; 2004; 17(2):279-86. PubMed ID: 15279705
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of immunological failure of antiretroviral therapy among HIV infected patients in Ethiopia: a matched case-control study.
    Teshome W; Asefa A
    PLoS One; 2014; 9(12):e115125. PubMed ID: 25536416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological and immunological responses to HAART in asymptomatic therapy-naive HIV-1-infected subjects according to CD4 cell count.
    Rizzardi GP; Tambussi G; Bart PA; Chapuis AG; Lazzarin A; Pantaleo G
    AIDS; 2000 Oct; 14(15):2257-63. PubMed ID: 11089613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Factors Related to CD4+ T-Cell Recovery and Viral Suppression in Patients Who Have Low CD4+ T Cell Counts at the Initiation of HAART: A Retrospective Study of the National HIV Treatment Sub-Database of Zhejiang Province, China, 2014.
    He L; Pan X; Dou Z; Huang P; Zhou X; Peng Z; Zheng J; Zhang J; Yang J; Xu Y; Jiang J; Chen L; Jiang J; Wang N
    PLoS One; 2016; 11(2):e0148915. PubMed ID: 26900702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A very low geno2pheno false positive rate is associated with poor viro-immunological response in drug-naïve patients starting a first-line HAART.
    Armenia D; Soulie C; Di Carlo D; Fabeni L; Gori C; Forbici F; Svicher V; Bertoli A; Sarmati L; Giuliani M; Latini A; Boumis E; Zaccarelli M; Bellagamba R; Andreoni M; Marcelin AG; Calvez V; Antinori A; Ceccherini-Silberstein F; Perno CF; Santoro MM
    PLoS One; 2014; 9(8):e105853. PubMed ID: 25153969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Growth, immune and viral responses in HIV infected African children receiving highly active antiretroviral therapy: a prospective cohort study.
    Musoke PM; Mudiope P; Barlow-Mosha LN; Ajuna P; Bagenda D; Mubiru MM; Tylleskar T; Fowler MG
    BMC Pediatr; 2010 Aug; 10():56. PubMed ID: 20691045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictors of CD4+ cell count response and of adverse outcome among HIV-infected patients receiving highly active antiretroviral therapy in a public hospital in Peru.
    López de Castilla D; Verdonck K; Otero L; Iglesias D; Echevarría J; Lut L; Gotuzzo E; Seas C
    Int J Infect Dis; 2008 May; 12(3):325-31. PubMed ID: 18546542
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4+ T cells under successful highly active antiretroviral therapy.
    Benito JM; López M; Lozano S; Ballesteros C; Martinez P; González-Lahoz J; Soriano V
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):373-81. PubMed ID: 15764953
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of baseline CD4(+) T cell counts on the efficacy of nevirapine-based highly active antiretroviral therapy in Chinese HIV/AIDS patients: a prospective, multicentric study.
    Liu ZY; Guo FP; Han Y; Qiu ZF; Zuo LY; Li YL; Li TS
    Chin Med J (Engl); 2009 Oct; 122(20):2497-502. PubMed ID: 20079166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of thymic function-related markers to predict early CD4 T-cell repopulation in adult HIV-infected patients on HAART.
    Ruiz-Mateos E; de la Rosa R; Soriano N; Martinez-Moya M; Rubio A; Sánchez-Quijano A; Lissen E; Leal M
    Antivir Ther; 2003 Aug; 8(4):289-94. PubMed ID: 14518697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV.
    Grabar S; Kousignian I; Sobel A; Le Bras P; Gasnault J; Enel P; Jung C; Mahamat A; Lang JM; Costagliola D
    AIDS; 2004 Oct; 18(15):2029-38. PubMed ID: 15577624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged statin administration does not act on the cell-mediated immunity of HIV-infected dyslipidemic patients treated with a steady and effective highly active antiretroviral therapy. A two-year prospective study of statin versus fibrate administration.
    Manfredi R; Calza L; Chiodo F
    J Biol Regul Homeost Agents; 2006; 20(1-2):1-9. PubMed ID: 18088548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naive T-cell depletion related to infection by X4 human immunodeficiency virus type 1 in poor immunological responders to highly active antiretroviral therapy.
    Delobel P; Nugeyre MT; Cazabat M; Sandres-Sauné K; Pasquier C; Cuzin L; Marchou B; Massip P; Cheynier R; Barré-Sinoussi F; Izopet J; Israël N
    J Virol; 2006 Oct; 80(20):10229-36. PubMed ID: 17005700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.